mass spectrometric immunoassay

At the AACR annual meeting, researchers highlighted genomics- and proteomics-informed research aimed at establishing more effective, targeted immunotherapies.

The proteomics firm is swapping 4 million of its shares for a 10 percent interest in CPR with the goal of moving into clinical trials and related research.

In Life Sciences, CEO Thomas Joyce noted a strong performance by Beckman Coulter, while in Diagnostics, he said Cepheid grew 25 percent year over year. 

The new European initiative promises to deliver multiple new tests and methods for improving the treatment of breast cancer and rectal cancer.

Carrier screens for cystic fibrosis, fragile X syndrome, and spinal muscular atrophy detected carrier status in one in 20 individuals and led to diagnoses in seven pregnancies.

Bioage Labs now intends to set up an internal laboratory to experiment with different compounds, while building out its team.

Announced during the company's recent analyst day, the instrument could mark a major step in mass spectrometry's ongoing move into clinical applications.

After years of technical setbacks and challenges, mass spec-based clinical proteomics is "ready for prime time," a Thermo Fisher Scientific researcher told ProteoMonitor this week.

Thermo Fisher Scientific last week announced a collaboration with German diagnostics firm Immundiagnostik for development of mass spec-based assays for protein and peptide quantitation.

Pages

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.